MedTrace Logo

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

NCT02065609 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-10-13

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.

Conditions

Interventions

DRUG

89Zr-Trastuzumab Human Dosimetry and Safety

PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety

DRUG

HER2 Positive Lesion Detection and Safety

Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Farrokh Dehdashti, MD · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-12-31
Completion
2018-02-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02065609 on ClinicalTrials.gov